Biotechnology News and Research RSS Feed - Biotechnology News and Research

Scientists develop new system to treat a host of genetic conditions

Scientists develop new system to treat a host of genetic conditions

As potential next-generation therapeutics and research tools, few life sciences technologies hold more promise than genome-editing proteins – molecules that can be programmed to alter specific genes in order to treat or even cure genetic diseases. [More]
New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

Oligonucleotide-based therapeutics present unique challenges when it comes to testing their potential to cause reproductive and developmental harm. New consensus guidelines for toxicity testing that take into consideration the combined chemical and biological characteristics of these novel biopharmaceuticals are presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. [More]
Study: New blood substitute may be safer than donor blood

Study: New blood substitute may be safer than donor blood

A new blood substitute has been developed which could be a safer and more effective alternative to using donor blood. [More]
Life science investment in Northern England: an interview with Dr Geoff Davison, CEO, Bionow

Life science investment in Northern England: an interview with Dr Geoff Davison, CEO, Bionow

There are a number of challenges, but primarily, it's access to funding. The recent BioCap Conference focussed on the access small businesses have to funding and how that's driven by changes in the market place. [More]
Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan Holdings Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, and Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, today announce that they have entered into a research collaboration in the area of osteoarthritis pain. [More]
MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research today announced it has acquired the assets of Kalamazoo, Mich.-based Jasper Clinical Research & Development, Inc. Jasper is a respected clinical research organization that provides early-stage human clinical testing of promising new drugs, and is well known to pharmaceutical and biotechnology companies worldwide. [More]
Research could pave way for more effective drugs to treat inflammation

Research could pave way for more effective drugs to treat inflammation

Six Case Western Reserve scientists are part of an international team that has discovered two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis. [More]
Oncolytics signs equity distribution agreement with Canaccord Genuity

Oncolytics signs equity distribution agreement with Canaccord Genuity

Oncolytics Biotech Inc. announced today that it has entered into an "at-the-market" (ATM) equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. [More]
Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced the opening of the Crown Bioscience US Research Center to be located at the David H. Murdock Research Institute (DHMRI), in Kannapolis, N.C. The new center, which will open in the 3rd quarter of 2014, represents significant U.S. market expansion for Crown. [More]
Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM), effective October 1, 2014. [More]
Amgen files lawsuit against Regeneron, Sanofi to prevent infringing manufacture of alirocumab

Amgen files lawsuit against Regeneron, Sanofi to prevent infringing manufacture of alirocumab

Amgen today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively "Sanofi"), and Regeneron Pharmaceuticals, Inc. ("Regeneron") for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. [More]
Scientists develop promising vaccination strategy to counteract RSV infection

Scientists develop promising vaccination strategy to counteract RSV infection

Respiratory Syncytial Virus causes severe respiratory tract infections and worldwide claims the lives of 160,000 children each year. Scientists at VIB and Ghent University have succeeded in developing a promising vaccination strategy to counteract this common virus infection. [More]
Inpatient palliative care can considerably reduce readmissions, hospital costs, shows study

Inpatient palliative care can considerably reduce readmissions, hospital costs, shows study

Palliative care provided in the hospital offers known clinical benefits, and a new study shows that inpatient palliative care can also significantly lower the cost of hospitalization and the rate of readmissions. [More]
Mexican students create zero calorie sweetener for people with diabetes, hypertension, obesity

Mexican students create zero calorie sweetener for people with diabetes, hypertension, obesity

Since Elsa Martinez was diagnosed with type II diabetes she made sure to be informed about those food products that wouldn't aggravate her health. [More]
Statement on Ebola epidemic

Statement on Ebola epidemic

The Ebola virus is spreading rapidly and to an unexpected extent. The outbreak does not follow the patterns experienced in the past and the virus shows a new disease dynamic in regions, where it has never been recorded before. For this reason, the German National Academy of Sciences Leopoldina, acatech – the German Academy of Science and Engineering, and the Union of the German Academies of Sciences and Humanities have presented a statement on the Ebola epidemic today. [More]
Scientists receive BBSRC funding to study how neural stem cells differ from each other

Scientists receive BBSRC funding to study how neural stem cells differ from each other

A team of scientists led by a researcher from Plymouth University has received funding of more than £400,000 from the Biotechnology and Biological Sciences Research Council to investigate how neural stem cells differ from each other. The study's findings could hold the key to the future use of neural stem cells in treatments to eradicate neurological conditions such as dementia and brain tumours. [More]

PhRMA launches new website to educate consumers about ABCs of health coverage

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched Access Better Coverage.org, a new website designed to educate consumers about the ABCs of health coverage and access to prescription medicines. [More]
Research opens door to potential new treatments for peripheral artery disease

Research opens door to potential new treatments for peripheral artery disease

Researchers have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness. [More]
C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland. [More]
FDA approves new hepatitis C drug, Harvoni

FDA approves new hepatitis C drug, Harvoni

Insurers and patients are decrying the cost for the new drug, nearly $95,000 for a 12-week course of treatment, which is more expensive than Gilead's other hepatitis C drug, Sovaldi. But unlike some hepatitis C treatments, Harvoni can be taken without injections usually given to hepatitis C patients. [More]